Client Story: G Company and Bioperfectus Success Story

Company news
2022-09-20

The beginning of Bioperfectus global footprint

G Company (The client’s full name was hidden) is an importer and distributor of molecular diagnostics products in Thailand and is trusted by the government and laboratories. It is the first client Bioperfctus cooperates oversea. The encounter between Bioperfectus and G Company dates back to 2016. Bioperfectus was G Company's supplier of gastrointestinal infectious diseases and life science products. During the COVID-19 pandemic, the partnership between the two sides became stronger. The client praised BioPerfectus for its outstanding performance and excellent service, especially during the pandemic.

 

COVID-19 broke out in December 2019 but didn’t come to global attention. As one of the leading international IVD suppliers, Bioperfectus was the first company to develop a COVID-19 real-time PCR Kit to fight against the COVID-19 crisis worldwide. In January 2020, the virus entered Thailand quietly, and there was an urgent need for COVID-19 real-time PCR Kits from G Company. Facing the challenge of a health emergency, Bioperfectus international sales team worked collaboratively with the customer service team to deliver integrated solutions that meet the client’s needs. With onsite support, the Bioperfectus team physically came to Bangkok, Thailand, and provided support for the client in person. The COVID-19 real-time PCR kits provided by Bioperfectus were also the first batch of COVID-19 test kits for laboratory diagnosis in Thailand.

*Picture caption: A laboratory personnel in Thailand is using Bioperfectus products.

 

Satisfy the needs of local laboratories

At the peak of the COVID-19 wave in Thailand, many laboratories need COVID-19 PCR kits with faster detection speed and more accurate testing results. The COVID-19 real-time PCR kit (detection for three genes) of Bioperfectus was optimized by R&D teams and was tested to verify its performance on clinically positive samples. Bioperfectus received much positive feedback from end-users from local laboratories that the optimization solution helped them to improve work efficiency with high performance. Most importantly, the solution effectively helped local government and regulators to manage the COVID-19 situation, infection prevention, and control.


*Picture caption: Bioperfectus R&D personnel are conducting an experiment.

 

Prompt support and professional service

Since May 2022, there has been a global increase in monkeypox cases reported from multiple countries where monkeypox is not usually seen. The situation with monkeypox in many regions was changing rapidly.  Bioperfectus was the first company to provide the monkeypox virus real-time PCR kit granted by CE Mark to the global market. The Bioperfectus has production capacity for raw materials and the development platform to rapidly produce specific primers and probes for the Monkeypox virus PCR test.

 

At the beginning of the monkeypox outbreak in May, Bioperfectus delivered monkeypox virus real-time PCR kits to laboratories worldwide for detection in local communities. In Thailand, confirmed cases of monkeypox had been reported. Bioperfectus quickly delivered monkeypox virus real-time PCR kits and provided training services for G Company. Infectious diseases spread rapidly, and individuals with viruses can spread the infection to many other people in their community. Bioperfectus is still in a race against time and a guardian of humankind.

 

Bioperfectus is a very reliable partner, and I was highly impressed by the sales and customer service teams' prompt support and professional service. I cannot thank this service enough for the wonderful communication and all the support and hard work. Thank you.” Chief Executive Officer -G Company, commented.  

 

As part of the work process, our international teams conducted a values workshop with sales, logistics, technical support, and service to create tailored solutions for our clients. We are great to see our partner grow their business with our support.”  Cassie Bao, Regional Sales Manager, Bioperfectus

MOST READ

Bioperfectus Supports Cholera Elimination

SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.

2022-11-30

Client Story: A Race Against Time

Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.

2022-11-15

Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).

2022-11-14